Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News RXi Pharmaceuticals Corp RXII

Healthcare Biotechnology
"RXi Pharmaceuticals Corp is a clinical-stage RNAi company developing therapeutics based on its proprietary self-delivering RNAi platform and Samcyprone, a topical immunomodulator, which address significant unmet medical needs."

Recent & Breaking News (NDAQ:RXII)

RXi Pharmaceuticals Announces Initiation of Phase 2a Keloid Study

PR Newswire April 29, 2014

RXi Pharmaceuticals to Present at ARVO 2014 Annual Meeting

PR Newswire April 28, 2014

RXi Pharmaceuticals Enters into Financing Facility with Lincoln Park Capital

PR Newswire April 22, 2014

RXi Pharmaceuticals Reports Full Year 2013 Financial Results

PR Newswire March 28, 2014

RXi Pharmaceuticals Announces Upcoming Presentations

PR Newswire March 14, 2014

RXi Pharmaceuticals Granted Key Patent Related to Self-Delivering Technology for the Treatment of Fibrotic Disorders

PR Newswire March 5, 2014

RXi Pharmaceuticals to Present at the 26th Annual ROTH Conference

PR Newswire March 4, 2014

RXi Pharmaceuticals to Present at the 24th Annual Wall Street Analyst Forum

PR Newswire February 24, 2014

OTC Markets Group Congratulates RXI Pharmaceuticals on NASDAQ Listing

PR Newswire February 11, 2014

RXi Pharmaceuticals Announces Listing on NASDAQ Capital Market

PR Newswire February 11, 2014

RXi Pharmaceuticals to Present at the 16th Annual BIO CEO & Investor Conference

PR Newswire February 3, 2014

RXI Pharmaceuticals Could Benefit from Biotech Industry Dynamics

Accesswire January 24, 2014

RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders

PR Newswire January 14, 2014

NIH Data Sharing Projects Could Accelerate RNAi Field

Accesswire January 8, 2014

RXi Pharmaceuticals to Present at the Biotech Showcase(TM) 2014

PR Newswire January 6, 2014

Surgical Scar Market Is Ripe for Innovation

Accesswire December 18, 2013

RXi Pharmaceuticals Announces mRNA Data of an Additional Cohort in the Second Phase 1 Multi-Dose Study with RXI-109, Extending the Dose Response Following Treatment in the Initial 2-week Period

PR Newswire December 4, 2013

RXi Pharmaceuticals to Present at the Piper Jaffray 25th Annual Healthcare Conference

PR Newswire November 27, 2013

RXi Pharmaceuticals Corporation and Ethicor Ltd. Announce the Signing of a Distribution Agreement for RXI-109 in the European Union under the "Specials" Provision

PR Newswire November 18, 2013

RXi Pharmaceuticals Reports Financial Results for the Third Quarter of 2013

PR Newswire November 14, 2013